Leading biopharmaceutical company Pfizer has unveiled Cibinqo and Staquis, two innovative therapies designed to address eczema across its varying stages, now available in Malaysia. The announcement, ...

The JP Morgan Healthcare Conference, which is being held in San Francisco this year, has been much more active than last year. Among some of the top news at the conference were M&A deal announcements ...

Like all cancers, bladder cancer develops when abnormal cells start to multiply out of control. But what if we could put a ...

R-5780, an oral immuno-oncology drug designed to activate gut-regulated immune pathways, will now be evaluated in a phase 1 ...

Technoderma Medicines has completed its phase 2a trial of TDM-180935 for the treatment of atopic dermatitis, demonstrating ...

Adults with type 2 diabetes using a GLP-1 receptor agonist have a similar risk for developing thyroid cancer as those using a ...

First subjects dosed in a Phase 2 trial of VTX3232 in participants with obesity and cardiometabolic risk factors, with topline data expected in H2 2025 Phase 2 trial of VTX2735 in participants with ...

Verastem (VSTM) announced it has exercised early the option to license from GenFleet Therapeutics VS-7375, an oral and selective KRAS G12D ...

H.C. Wainwright analyst Joseph Pantginis has maintained their bullish stance on BMEA stock, giving a Buy rating yesterday.Stay Ahead of the ...

Munich, Germany, January 14, 2025 - Vivoryon Therapeutics N.V. (Euronext Amsterdam: VVY; NL00150002Q7) (Vivoryon), a clinical ...

ORPATHYS ® is an oral, potent and highly selective MET TKI that has demonstrated clinical activity in advanced solid tumors. It blocks atypical activation of the MET receptor tyrosine kinase pathway ...

After selling its PI3Kα program to Eli Lilly, Scorpion will spinout out a different entity, which will be owned by the ...